LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system for obesity and metabolic disorders. The company was incorporated in 2024 and is based in Vancouver, Canada.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-22
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
News release - English.pdf
News 2026-04-29
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
News release - English.pdf
News 2026-04-20
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
News release - English.pdf
Results 2026-04-01
Interim MD&A - English.pdf
Results 2026-04-01
Interim financial statements/report – English.pdf
News 2026-02-05
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
News release - English.pdf
News 2026-01-29
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
News release - English.pdf
News 2026-01-22
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
News release - English.pdf
News 2026-01-15
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
News release - English.pdf
News 2026-01-08
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
News release - English.pdf
Results 2025-12-29 Financials
Financial statements of RTO acquirer.pdf
Results 2025-12-29 Financials
Interim MD&A - English.pdf
Results 2025-12-29 Financials
Interim financial statements/report – English.pdf
News 2025-12-11
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
News release - English.pdf
News 2025-12-10
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
News release - English.pdf
News 2025-11-27
Lir Life Sciences Announces Engagement for IR Services
News release - English.pdf
News 2025-11-21
Letter from successor auditor.pdf
News 2025-11-21
Cover letter.pdf
News 2025-11-21
Notice.pdf
News 2025-11-21
Letter from former auditor.pdf
News 2025-11-11
Material change report - English.pdf
News 2025-11-11
News release - English.pdf
News 2025-11-11
Notice.pdf
News 2025-11-11
Other securityholders documents - English.pdf
News 2025-11-05
News release - English.pdf
News 2025-11-05
Cover letter.pdf
News 2025-11-04
Certificate and articles of change of name.pdf
Transactions 2025-11-04
Other material contracts - English.pdf
Transactions 2025-11-04
Other material contracts - English.pdf
Transactions 2025-11-04
Other material contracts - English.pdf
Transactions 2025-11-04
Other material contracts - English.pdf
News 2025-11-04
Filing statement - English.pdf
Results 2025-10-07 Financials
Interim MD&A - English.pdf
Results 2025-10-07 Financials
Interim financial statements/report – English.pdf
News 2025-08-15
Material change report - English.pdf
Transactions 2025-08-15
Other material contracts - English.pdf
News 2025-08-15
News release - English.pdf
Results 2025-08-13 Financials
Annual MD&A - English.pdf
Results 2025-08-13
Annual MD&A - English.pdf
Results 2025-08-13
Audited annual financial statements – English.pdf
Results 2025-08-13 Financials
Audited annual financial statements – English.pdf
News 2025-07-17
Report of exempt distribution (45-106F1).pdf
News 2025-07-17
Material change report - English.pdf
News 2025-07-14
News release - English.pdf
News 2025-07-14
News release - English.pdf